Chardan Capital Reiterates Buy on Alnylam Pharmaceuticals, Maintains $250 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Keay Nakae has reiterated a 'Buy' rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $250.
August 08, 2023 | 11:43 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital has reiterated a 'Buy' rating on Alnylam Pharmaceuticals and maintained a price target of $250.
The reiteration of a 'Buy' rating by Chardan Capital indicates a positive outlook for Alnylam Pharmaceuticals. The maintained price target of $250 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100